Neuralytix, LLC

 Press Releases

• Neuralytix Announces Full Commercial Availability of the iD3 System (Aug 12, 2026)

  FRUITA, CO — August 4, 2026 — Neuralytix, LLC (www.nerve.health) today announced full commercial availability of its iD3 System, an FDA 510(k)-cleared mechanomyography (MMG) platform that gives spine surgeons real-time, objective feedback on neurophysiologic changes occurring throughout decompression surgery. The launch builds on the system's initial commercial release in October 2025 and is now available through Neuralytix' U.S. distributor network.

  The iD3 System is surgeon-directed and requires no dedicated technician or neurophysiologist — it integrates directly into existing surgical workflow. Using MMG, it measures how nerves are conducting and responding throughout decompression, giving surgeons a quantitative readout in an assessment that has traditionally relied on visual and anatomical judgment alone.

  "At the end of every nerve decompression procedure, surgeons face the same question: is the nerve adequately decompressed?" said Christopher Wybo, Founder and CEO of Neuralytix. "Cardiology pairs the angiogram with the stress test because structure and function often diverge. With iD3, we're bringing that same functional stress test to spine surgery."

  About Neuralytix, LLC

  Neuralytix develops mechanomyography (MMG) technology for objective, real-time intraoperative nerve assessment during spine surgery. The iD3 System is FDA 510(k) cleared (K243636/K260992).

• Neuralytix Recognizes Dr. Ross Jones as a Pioneering Voice in MMG-Guided Sp (Aug 12, 2026)

  FRUITA, CO - August 6, 2026 - Neuralytix, LLC (www.nerve.health) today recognized Dr. Ross Jones, DO, an orthopaedic spine surgeon at Flagstaff Bone & Joint in Flagstaff, Arizona, as one of the first surgeons to adopt mechanomyography (MMG) as an intraoperative decompression endpoint, and as a foundational contributor to the growing peer-reviewed evidence base behind the approach.

  Dr. Jones is a co-author of a 2025 pilot study in the Journal of Personalized Medicine, which followed 42 patients across 112 nerve decompressions and found that MMG threshold metrics anchored to a physiologic reference point were more predictive of post-operative pain relief than simple percentage-based threshold change (Abdulhak et al., 2025).

  He is also lead author of a newly published 600-patient retrospective study in the North American Spine Society Journal comparing his own surgical outcomes before and after routinely adopting intraoperative MMG as a decompression endpoint (Jones & Nay, 2026). The study, which used a predicate MMG system prior to the iD3 System's commercial availability, found that 90-day unplanned return to the operating room fell from 9.7% to 2.7%, incidental durotomy fell from 9.7% to 2.3%, and mean 3-month pain scores improved from 4.91 to 1.93 on a 10-point scale. As a retrospective, single-surgeon analysis, the study's authors describe the findings as hypothesis-generating and call for prospective multicenter validation - but the magnitude and consistency of the association mark one of the most substantial single-surgeon adoption studies published on MMG to date.

  "We can build the technology, but only surgeons can tell us whether it belongs in the OR." —  said Christopher Wybo, Founder and CEO of Neuralytix. "Dr. Jones has spent five years asking hard questions and testing them with data —  and the outcomes he's seeing are exactly the kind of signal that makes us optimistic about what MMG can mean for patients." 

  About Neuralytix, LLC

  Neuralytix develops mechanomyography (MMG) technology for objective, real-time intraoperative nerve assessment during spine surgery. The iD3 System is FDA 510(k) cleared (K243636/K260992).